FY2024 EPS Forecast for Co-Diagnostics Increased by Analyst

Posted by Ethan Ryder on Nov 15th, 2024

Co-Diagnostics, Inc. (NASDAQ:CODX – Free Report) – Equities research analysts at HC Wainwright raised their FY2024 earnings estimates for shares of Co-Diagnostics in a report issued on Monday, November 11th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($1.22) for the year, up from their prior estimate of ($1.23). HC Wainwright currently has a “Neutral” rating and a $1.50 target price on the stock. The consensus estimate for Co-Diagnostics’ current full-year earnings is ($1.23) per share. HC Wainwright also issued estimates for Co-Diagnostics’ Q4 2024 earnings at ($0.34) EPS, Q1 2025 earnings at ($0.34) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.24) EPS and FY2025 earnings at ($1.17) EPS.

Co-Diagnostics Stock Down 0.9 %

NASDAQ:CODX opened at $1.10 on Thursday. The firm has a market capitalization of $35.12 million, a PE ratio of -0.80 and a beta of -0.84. Co-Diagnostics has a 12-month low of $1.00 and a 12-month high of $2.23. The firm has a 50-day moving average price of $1.24 and a 200 day moving average price of $1.26.

Institutional Investors Weigh In On Co-Diagnostics

A hedge fund recently bought a new stake in Co-Diagnostics stock. Koss Olinger Consulting LLC purchased a new stake in Co-Diagnostics, Inc. (NASDAQ:CODX – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 58,887 shares of the company’s stock, valued at approximately $74,000. Koss Olinger Consulting LLC owned approximately 0.19% of Co-Diagnostics at the end of the most recent reporting period. Institutional investors own 14.99% of the company’s stock.

Co-Diagnostics Company Profile

(Get Free Report)

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.